



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

OR-1855

Cat. No.:	HY-W050000
CAS No.:	101328-85-2
Molecular Formula:	C ₁₁ H ₁₃ N ₃ O
Molecular Weight:	203.24
Target:	Potassium Channel; Phosphodiesterase (PDE); Autophagy
Pathway:	Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Autophagy
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (492.03 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM	4.9203 mL	24.6015 mL	49.2029 mL	
		5 mM	0.9841 mL	4.9203 mL	9.8406 mL	
		10 mM	0.4920 mL	2.4601 mL	4.9203 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (12.30 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (12.30 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	OR-1855, an active metabolite of Levosimendan, has effect on human myometrial contractility. Levosimendan is a calcium sensitizer used in the management of acutely decompensated congestive heart failure ^{[1][2]} .
-------------	--

REFERENCES

- [1]. Banfor PN, et al. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O₂ consumption in dogs. Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H238-48.
- [2]. Mark P. Hehir, et al. 487: OR-1855, a levosimendan metabolite with an effect on human myometrial contractility. December 2009 Volume 201, Issue 6, Supplement, Pages S182-S183.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA